These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis. Martin U; Dörge L; Fischer S Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626 [TBL] [Abstract][Full Text] [Related]
63. Antihemostatic and antithrombotic effects of monoclonal antibodies against von Willebrand factor in nonhuman primates. Krupski WC; Bass A; Cadroy Y; Kelly AB; Harker LA; Hanson SR Surgery; 1992 Aug; 112(2):433-9; discussion 439-40. PubMed ID: 1641780 [TBL] [Abstract][Full Text] [Related]
64. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation; 1994 Oct; 90(4):1631-7. PubMed ID: 7923645 [TBL] [Abstract][Full Text] [Related]
66. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657 [TBL] [Abstract][Full Text] [Related]
67. Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. Buchwald AB; Sandrock D; Unterberg C; Ebbecke M; Nebendahl K; Lüders S; Munz DL; Wiegand V J Am Coll Cardiol; 1993 Jan; 21(1):249-54. PubMed ID: 7678021 [TBL] [Abstract][Full Text] [Related]
68. Combined administration of barbourin--albumin and hirudin--albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta. Sheffield WP; Gataiance S; Eltringham-Smith LJ Thromb Res; 2007; 119(2):195-207. PubMed ID: 16478628 [TBL] [Abstract][Full Text] [Related]
69. The characterisation of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Peters RF; Lees CM; Mitchell KA; Tweed MF; Talbot MD; Wallis RB Thromb Haemost; 1991 Mar; 65(3):268-74. PubMed ID: 1710836 [TBL] [Abstract][Full Text] [Related]
70. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits. Kouz J; Czech J; Nicolay U; Dickneite G Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128 [TBL] [Abstract][Full Text] [Related]
71. Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin. McBane RD; Hassinger NL; Mruk JS; Grill DE; Chesebro JH Thromb Res; 2005; 116(6):525-32. PubMed ID: 16181988 [TBL] [Abstract][Full Text] [Related]
72. A technique to investigate microvascular mural thrombus formation in arteries and veins: II. Effects of aspirin, heparin, r-hirudin, and G-4120. Stockmans F; Stassen JM; Vermylen J; Hoylaerts MF; Nyström A Ann Plast Surg; 1997 Jan; 38(1):63-8. PubMed ID: 9015542 [TBL] [Abstract][Full Text] [Related]
73. Direct thrombin inhibitors in cardiac disease. Weitz JI; Bates ER Cardiovasc Toxicol; 2003; 3(1):13-25. PubMed ID: 12668887 [TBL] [Abstract][Full Text] [Related]
74. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840 [TBL] [Abstract][Full Text] [Related]
75. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins. Zhang B; Wieslander JB Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063 [TBL] [Abstract][Full Text] [Related]
76. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir). Schneider J; Wnendt S; Saunders D; Heinzel-Wieland R; Wilffert B; Steffens G Eur J Pharmacol; 1996 Apr; 302(1-3):69-77. PubMed ID: 8790994 [TBL] [Abstract][Full Text] [Related]
77. Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery. Rübsamen K; Kirchengast M Coron Artery Dis; 1998; 9(1):35-42. PubMed ID: 9589189 [TBL] [Abstract][Full Text] [Related]
78. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Vogel GM; van Amsterdam RG; Kop WJ; Meuleman DG Thromb Haemost; 1993 Jan; 69(1):29-34. PubMed ID: 8446935 [TBL] [Abstract][Full Text] [Related]
79. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Gruber A; Hanson SR; Kelly AB; Yan BS; Bang N; Griffin JH; Harker LA Circulation; 1990 Aug; 82(2):578-85. PubMed ID: 2372904 [TBL] [Abstract][Full Text] [Related]
80. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial. Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]